
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67544
Endocrinology/Diabetes/Metabolism
Dentistry
Internal Medicine
Interlinked Pathways: Exploring the Bidirectional Impacts of Periodontitis and Metabolic Syndrome
Muacevic Alexander
Adler John R
Barnawi Bandar M 1
Alanazi Maram M 2
Al-Mutiri Fai A 2
Alqahtani Rahaf S 2
Al-harbi Madhawi S 2
Al-Raqqas Saud K 3
Mahjoub Waleed K 4
Alsetri Mahdi M 4
Al-Sultan Ziyad M 4
Alghamdi Ghadeer M 5
Almutawah Ridha I 6
1 Family Dentistry, Ministry of Health, Medinah, SAU
2 College of Dentistry, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU
3 Dentistry, King Abdulaziz Medical City Riyadh, Riyadh, SAU
4 College of Dentistry, King Saud University, Riyadh, SAU
5 Dentistry, Ministry of Health, Dammam, SAU
6 Dentistry, King Faisal University, Alhfuf, SAU
Bandar M. Barnawi dr.barnawi@hotmail.com
22 8 2024
8 2024
16 8 e6754422 8 2024
Copyright © 2024, Barnawi et al.
2024
Barnawi et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/284670-interlinked-pathways-exploring-the-bidirectional-impacts-of-periodontitis-and-metabolic-syndrome
Metabolic syndrome (MBS) and periodontitis are distinct conditions with overlapping and unique risk factors. Periodontitis is a chronic destructive disease of the periodontium, driven by alterations in the host immune-inflammatory response to virulent periodontal pathogens. MBS is characterized by various abnormalities, including visceral abdominal obesity, dyslipidemia (low high-density lipoprotein (HDL) and high triglyceride (TG) levels), hypertension, and hyperglycemia. These factors collectively increase the risk of atherosclerotic cardiovascular disease (CVD) and diabetes. Several pro-inflammatory mediators are involved in the pathogenesis of periodontitis and MBS, and the deleterious bidirectional effects of these mediators exacerbate the severity and progression of both conditions. This comprehensive review focuses on the intricate relationship between MBS and periodontitis. Specifically, it explores the pathophysiological mechanisms of each disease component of MBS and its impact on periodontitis, and vice versa.

cytokines
insulin resistance
inflammation
metabolic syndrome
periodontitis
==== Body
pmcIntroduction and background

Periodontal disease (PD) is a low-grade chronic inflammatory disease, featuring a dysbiotic microbial community that causes a shift in the subgingival microbiota from Gram-positive to Gram-negative. This shift triggers the host immune-inflammatory system, leading to the destruction of the investing periodontal apparatus of the tooth [1-3]. The resultant persistent low-intensity inflammation by PD without intervention contributes to a characteristic systemic inflammatory state that has been linked to various systemic diseases such as cardiovascular diseases [4], obesity [5], insulin resistance (IR) [6], and metabolic syndrome (MBS) [7]. The inflammatory mediators that are released as a consequence of host-microbial interaction in PD include the proinflammatory cytokines such as interleukin (IL-1β) and tumor necrosis factor-alpha (TNF-α) that are upregulated in correlation with raised concentrations of prostaglandin E2 (PGE2) and elevated levels of C-reactive protein (CRP). The presence of these mediators is evident not only in periodontitis but also in systemic conditions like diabetes, obesity, and arthritis [8]. Around 20 to 60% of the global population is estimated to be impacted by varying degrees of periodontal disease [9-12], with approximately 7.4% of individuals, equivalent to 538 million people, suffering from a more severe form of periodontitis [13].

The sustained low-grade inflammatory condition may precipitate the emergence of IR and perturb the delicate balance of cytokine interactions within the periodontal tissues [14,15]. The induction of a proinflammatory state as a consequence of IR is purported to be a potential contributor to the development of MBS [16]. In 1988, Dr. Gerald Reaven introduced the term "Metabolic Syndrome", also known as "Reaven’s Syndrome" [17], "Insulin Resistance Syndrome" and "Syndrome X". This syndrome encompasses a collection of metabolic or systemic abnormalities, including hypertension, dyslipidemia, IR, and central obesity. The inflammatory state caused by these interconnected systemic abnormalities of MBS is associated with endothelial dysfunction which collectively elevates the likelihood of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) [18,19]. The potential linkage between metabolic syndrome and periodontal disease is posited to arise from their shared characteristic of being influenced by inflammatory responses, inflammatory cytokines, and heightened systemic oxidative stress [20]. The prevalence of metabolic syndrome demonstrates an age-dependent increase and exhibits variability across diverse ethnicities and genders within populations [21]. In contemporary times, metabolic syndrome has gained acknowledgment as a notable global epidemiological concern, with prevalence rates ranging from 17% to 32% in the general population [22].

This comprehensive review seeks to explore the correlation between MBS and periodontitis, focusing on elucidating the bidirectional impacts of the MBS cluster and periodontitis, including factors such as inflammatory responses, oxidative stress, biochemical changes, and microbiological effects. Additionally, it will investigate common risk factors shared between MBS and periodontitis, alongside individual discussions on the components of MBS, incorporating the latest evidence from the literature.

Review

Research methodology

A comprehensive search was conducted on digitized databases, including PubMed, Embase, Medline, and Google Scholar, utilizing specific keywords such as “periodontitis,” “metabolic syndrome,” “insulin resistance,” “hyperglycemia,” “obesity,” “dyslipidemia,” and “hypertension.” The initial screening involved identifying relevant articles through title and abstract reviews, followed by full-text evaluations of the selected studies.

The inclusion criteria for this review comprised narrative reviews, systematic reviews, randomized controlled trials, comparative studies, clinical trials, and case series focusing on the bidirectional impacts of periodontitis and metabolic syndrome. Studies that examined inflammatory markers, microbial changes, systemic impacts, and patient outcomes related to both conditions were included.

Conversely, studies that focused solely on surgical interventions, antimicrobial therapies, or conditions unrelated to periodontitis and metabolic syndrome were excluded. Additionally, articles that did not provide specific data on the interaction between periodontitis and metabolic syndrome or those lacking sufficient methodological detail were omitted from this review.

Overview of periodontitis as an inflammatory disease

Severe periodontitis is recognized as the sixth most commonly occurring disease worldwide and represents a significant contributor to disability-adjusted life years within oral health conditions [23]. The etiology of periodontal disease involves a multifactorial interplay of bacterial plaque and dental biofilm, microbial by-products, the host's immune response, environmental and behavioral influences, and genetic predispositions [24]. While the presence of bacteria is a fundamental element in the progression of periodontitis, it is not solely responsible for the onset of the disease. Subgingival microorganisms and their deleterious products, such as lipopolysaccharides (LPS), reach the systemic circulation and the investing periodontal tissues through ulcerations of the sulcular epithelium, stimulating macrophages to secrete cytokines such as IL-1α, IL-1β, and TNF-α [1,25].

In the absence of disease-modifying risk factors, the body typically responds in a way that limits bacterial buildup and mitigates the likelihood of infection. Coexisting comorbidities such as diabetes and smoking can disrupt this normal immune-inflammatory response and drive it beyond its usual physiological limits. In the context of immune responses, both the antibody-mediated and cell-mediated pathways are activated, but the adverse effects are caused by disrupted repair processes or exaggerated inflammatory reactions [26]. Elevated levels of cellular and cytokine-mediated inflammatory markers, including CRP [27], fibrinogen [28,29], matrix metalloproteinases (MMPs) [30], and various cytokines [31], have been linked to periodontitis.

In PD, the bacterial load interacts with the innate immune system through mechanisms that involve the recruitment of neutrophils, macrophages, monocytes, and mast cells to the site of infection. This process triggers elevated levels of cytokines in response to bacterial invasion, contributing to recurrent cell recruitment and complement activation, which in turn leads to additional tissue damage. PGE2, a hormone with local effects, induces the release of MMPs from macrophages, fibroblasts, and endothelial cells, resulting in the degradation of the extracellular matrix. This leads to a cascade of events [24], where TNF-α, PGE2, IL-1β, IL-6, IL-11, and IL-17 elevate the activity of receptor activator of nuclear factor kappa-B ligand (RANK-L). The interaction of RANK-L with its receptor RANK activates a pathway that triggers osteoclast differentiation, ultimately resulting in crestal bone loss [1,24,32].

The inflammatory processes and immune responses involved in periodontitis have broader implications for systemic health, particularly in the context of metabolic conditions. One such condition is metabolic syndrome, which shares several overlapping risk factors and pathogenic mechanisms with periodontitis.

Metabolic syndrome

MBS is a collective cluster of conditions that increase the risk of developing CVD and T2DM. Obesity, insufficient physical activity, and IR are the primary risk factors for MBS. Factors such as advancing age, genetic predisposition, and hormonal imbalances further increase this risk [14].

The diagnostic criteria for MBS are primarily based on several core components: central obesity, low high-density lipoprotein (HDL) cholesterol, elevated triglyceride (TG) levels, increased blood pressure, and elevated blood glucose levels [20]. Various professional organizations have developed distinct sets of diagnostic criteria for MBS, but all of them emphasize these fundamental components. Initially, the widely adopted framework was the National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) [20,33], later revamped by the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) in 2005 [14]. Both iterations require the presence of at least three out of the five aforementioned components for a metabolic syndrome diagnosis.

Additionally, the International Diabetes Federation (IDF) and the World Health Organization (WHO) formulated specific diagnostic guidelines of their own. The IDF criteria notably highlight central obesity as a pivotal criterion, distinguishing it from the criteria used by the NCEP ATP III and AHA/NHLBI [14]. Conversely, the WHO criteria states glucose intolerance, impaired glucose tolerance, or diabetes, alongside IR, as integral components for diagnosing MBS [34]. For standardization purposes, metabolic syndrome is defined as the presence of three out of the aforementioned five interconnected conditions [18]. The predominant components characterizing metabolic syndrome commonly include abdominal adiposity, hypertension, and hyperglycemia [35].

Correlation between metabolic syndrome and periodontal disease

The primary connection between MBS and periodontal disease lies in the interaction between oxidative stress and microbial dysbiosis, resulting from their similar inflammatory characteristics [20,36]. In periodontal disease, pro-inflammatory cytokines migrate from the gingiva into the vascular circulation, thus elevating oxidative stress. This worsens IR and promotes atherosclerotic changes, which predispose individuals to metabolic syndrome. Similarly, in metabolic syndrome, inflammatory cytokines may intensify gingival oxidative stress and, therefore, weaken the periodontium's capacity to handle bacterial assaults. This increases susceptibility to periodontal disease, producing a reciprocal association [20].

Obesity and type 2 diabetes can alter the composition of the oral microbiome, resulting in a state of microbial imbalance [36]. Obese individuals with periodontal disease exhibit distinct differences in their oral microbiome composition compared to their non-obese counterparts. Specifically, obese patients demonstrate reduced oral microbial diversity, and this could increase their vulnerability to periodontal disease [37].

Two hypotheses exist regarding the correlation between periodontitis and metabolic syndrome: one suggests a causal relationship, while the other emphasizes common risk factors. Both conditions share risk factors like hyperglycemia, obesity, dyslipidemia, and high blood pressure, along with confounding elements such as excessive calorie consumption, lack of physical activity, and poor oral hygiene. Evidence also indicates a reciprocal connection, where inflammatory markers in metabolic syndrome can worsen periodontal inflammation and vice versa [1,38,39].

In a previous study, subjects diagnosed with MBS displayed elevated concentrations of plasminogen activator inhibitor type-1 (PAI-1) compared to their healthy counterparts [40]. The involvement of PAI-1, along with tissue plasminogen activator, is integral to the pathogenesis of periodontitis through the modulation of extracellular matrix proteolysis. Furthermore, obesity can impact PAI-1 levels, potentially exacerbating the progression of periodontitis [1,41]. Accordingly, Nishimura et al. proposed that periodontal disease should be considered a component of MBS [42].

Gomes-Filho et al. [43] conducted a case-control study and found that individuals with moderate to severe periodontitis had a twofold increased risk of MBS compared to those without the condition. This increased risk was higher in severe cases, indicating a positive association between the severity of periodontitis and MBS. In their systematic review, Rosário-dos-Santos et al. [44] elucidated that moderate and severe levels of periodontitis are associated with MBS, indicating a potential dose-response relationship. In addition, Pham et al. [45] discovered that a substantial proportion (21%) of individuals diagnosed with metabolic syndrome had severe periodontitis, compared with the lower prevalence (6.8%) observed among healthy counterparts. Moreover, elevated levels of periodontal indicators, including bleeding on probing (BOP), gingival index (GI), plaque index (PI), probing pocket depth (PPD), and clinical attachment level (CAL), were noted among those with metabolic syndrome. They observed a correlation between the number of metabolic syndrome components and the worsening severity of periodontal disease, with those having four to five components displaying the poorest periodontal parameters. Understanding metabolic syndrome is crucial, as its components significantly influence and are influenced by various chronic conditions, including periodontitis. A key factor in this relationship is insulin resistance, a cornerstone of metabolic syndrome and a significant player in periodontal disease.

Insulin resistance and periodontitis

IR is a metabolic disorder characterized by a decrease in the effectiveness of insulin on tissues in response to normal levels of insulin. It results in elevated blood glucose levels and is classified as a precursor to diabetes. Prediabetes is recognized as a component of MBS due to its correlation with IR, and it is also a strong indicator of developing T2DM [33,46].

MBS is often attributed to the effects of IR, which initiates a pro-inflammatory state. IR arises when the pancreas produces insulin that is incompletely utilized by muscle, fat, and liver cells due to impaired signaling, consequently diminishing glucose metabolism from the bloodstream [47]. As a result, inflammation occurs due to various mechanisms, such as oxidative stress, increased concentration of free fatty acids, and interactions with the anti-inflammatory effects of insulin [48]. Advanced glycation end products (AGEs) interacting with their receptors (RAGEs) promote local oxidative damage and act as markers for systemic oxidative stress, which is heightened in MBS [49]. Furthermore, enlarged waist circumference and elevated body mass index (BMI) are closely associated with IR; these factors are linked to visceral adipose tissue accumulation and enhanced adiposity. Subsequently, adipocytes and macrophages in adipose tissue produce cytokines, such as TNF-α and IL-6. These molecules are associated with pro-inflammatory activity and are involved in the development of IR [50], with elevated circulating levels of TNF-α and IL-6 found in subjects with obesity and IR [51].

Researchers have found correlations between IR and periodontal disease. In one study, individuals previously diagnosed with IR showed a markedly higher occurrence of moderate to severe periodontal disease compared to their healthy counterparts [52]. One potential explanation for the link between periodontal disease and IR could be the inflammatory process [53]. IR is characterized as a low-intensity, chronic inflammatory state. In cases of IR, there is an increase in pro-inflammatory molecules like interleukin IL-1, IL-6, and TNF-α [54,55]. Another inflammatory agent that may be associated with the condition is reactive oxygen species (ROS) [56].

The relationship between IR and periodontal disease is believed to be reciprocal. Periodontal disease is characterized by chronic inflammation, leading to the release of pro-inflammatory cytokines in the gingiva, which can enter the bloodstream and potentially exacerbate preexisting IR or contribute to the onset of diabetes mellitus [46]. In addition to the inflammatory pathway, the microbial approach is also implicated in the association between IR and periodontitis. In an in vitro study, lipopolysaccharides from Porphyromonas gingivalis were observed to have a significant influence on the advancement of β-cell compensation and IR among individuals in the prediabetic stage with periodontitis [57]. Another critical aspect of metabolic syndrome that closely interacts with periodontitis is hyperglycemia, particularly in the context of type 2 diabetes mellitus.

Hyperglycemia and periodontitis

T2DM is a prevalent metabolic disorder characterized by impaired regulation of glucose levels in the body. This condition arises from a continual decline in the functioning of β cells and high levels of glucose in the blood. The inability of β cells to adequately counteract IR leads to the development of T2DM, making IR a key element of T2DM [58].

Hyperglycemia is the most well-documented element of metabolic syndrome in association with periodontal disease. The proposed explanations for this relationship focus on the release of AGEs, oxidative stress, and inflammation. Elevated levels of oxidative stress and ongoing subclinical inflammation throughout the body hinder the regulation of blood sugar levels and promote IR, thereby creating a pathway for the development of T2DM [59,60]. AGEs then build up due to the non-enzymatic glycation of proteins by persistently high blood sugar levels, leading to increased oxidative stress in the periodontium and higher levels of RANKL expression. AGEs also stimulate macrophages to produce inflammatory cytokines, which play a crucial role in triggering the release of acute-phase reactants such as C-reactive protein, thereby worsening the existing inflammation [61].

Individuals who have diabetes and severe periodontitis exhibit impaired chemotaxis, phagocytosis, and altered superoxide production by polymorphonuclear leukocytes (PMNs). Subsequently, killing capacity is compromised, and dysfunctional PMNs accumulate in periodontal tissues, ultimately causing an abscess-like state [56,62,63]. Individuals diagnosed with T2DM with periodontitis typically exhibit elevated biomarkers and oxidative stress markers. This raised oxidative stress may detrimentally impact β-cell function and further exacerbate IR. In periodontitis, elevated oxidative stress arises from an exaggerated neutrophil response that culminates in the increased release of ROS. Furthermore, there is evidence of diminished plasma antioxidant capacity in this population [6,64].

Metabolic pathways such as the polyol pathway [65], the hexosamine pathway [66], and the activation of protein kinase C (PKC) [67] elevate oxidative stress during hyperglycemia. Pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-18, elevated due to IR caused by diabetes, contribute to general body inflammation, thereby influencing bone loss and periodontal breakdown [46,66]. MMPs activated by these cytokines coalesce with ROS, leading to periodontal breakdown and collagen deterioration [68,69]. |Diabetes increases the ratio of RANKL/OPG and paves the way for osteoclastogenesis activation, resulting in deeper pockets, increased probing depth, and periodontal bone loss [69].

Patients with diabetes show reduced oral biological and phylogenetic diversity [70-72] as well as less species diversity. However, they have a higher abundance of periodontopathic microorganisms than healthy controls [70,72-74]. A similar pattern was observed in the subgingival microbiome environment, indicating that although patients with diabetes may appear to have a healthy periodontium, they have a higher risk of developing periodontal disease [72-74].

Quadri et al. conducted research in Saudi Arabia to examine the potential reciprocal correlation between periodontitis and T2DM. Their findings demonstrated a significant link between T2DM and hypertension among individuals with periodontitis. Numerous other studies have reported a moderate decline of 0.4% in the average hemoglobin A1C (HbA1C) level among diabetic individuals undergoing non-surgical interventions for periodontal disease [75,76]. After three months, diabetic subjects undergoing scaling experienced an average reduction in HbA1c levels of 0.3%. This is clinically significant, as a mere 1% drop in HbA1c levels has been linked to a remarkable 21% drop in diabetes-related mortality and a 37% drop in microvascular complications [75]. In 2023, a systematic review and meta-analysis evaluated the impact of poorly controlled diabetes mellitus on the development or progression of periodontitis; it showed an 86% increased risk associated with poorly managed diabetes mellitus, indicating an increased vulnerability to periodontitis among individuals with diabetes [77]. Alongside hyperglycemia, obesity is another critical factor within metabolic syndrome that exerts substantial effects on periodontal health.

Obesity and periodontitis

Obesity, a chronic multifactorial disease, is an imbalance of energy metabolism that manifests as an accumulation of excess fatty tissue posing a health risk [78-80]. The BMI is the primary method of measuring body fat [81]. A BMI exceeding 30 kg/m² is classified as obese, while a BMI between 25 and 29.99 kg/m² is categorized as overweight. An overweight individual is defined as having a waist circumference greater than 90 cm for women or 100 cm for men. An obese individual is characterized as having a waist circumference exceeding 105 cm for women or 110 cm for men [82]. In 2022, the WHO reported a concerning rise in obesity across Europe post-COVID-19, particularly among adolescents and children [83]. The buildup of fat tissue, especially around the abdomen (abdominal obesity), is linked to more than 200 health complications, such as T2DM, hypertension, and dyslipidemia, all of which are key components of MBS [84].

The connection between obesity and periodontal disease is increasingly evident in those with higher BMIs [85]. Increased waist circumference, weight gain, obesity, and being overweight are potential risk factors for periodontitis [5,86,87]. Adipose tissue is actively involved in influencing inflammation and immunity; it secretes both pro- and anti-inflammatory molecules, including adiponectin, cytokines, and chemokines, in a disrupted or modified manner [88]. The hallmark of inflammation induced by adipose tissue in obesity is its impact on multiple organs such as the pancreas, liver, skeletal muscle, heart, and brain [89]. The significant role of adipose tissue in systemic inflammation in obesity is linked to its secretion of hormones and cytokines, which play a crucial role in the development of various comorbidities associated with obesity [90].

As mentioned earlier, adipocytes and macrophages within adipose tissue secrete TNF-α and IL-6, which influence the relationship between obesity and periodontitis [91,92]. These cytokines, often termed adipocytokines, modulate systemic inflammation by influencing insulin sensitivity and glucose metabolism via chemokine signaling pathways. IL-6 contributes to reduced insulin signaling, increased fatty acid oxidation, and elevated hepatic synthesis of CRP. Conversely, TNF-α promotes lipolysis and upregulates IL-6 expression in adipocytes and processes associated with IR [93,94]. The development of IR and periodontitis may be significantly influenced immunologically by these adipokines. According to Han et al. [95], the best marker to evaluate the correlation between obesity and periodontitis is the visceral fat area, thus indicating obesity as a major risk factor for periodontitis.

Obesity increases the presence of ROS, which in turn triggers the activation of chronic inflammatory mediators within the gingiva, including the cytokines discussed earlier. This process leads to bone loss, deeper probing depths, and attachment loss in periodontal tissues [96]. Furthermore, obesity could disrupt the development of osteoblasts due to the common origin of adipocytes and osteoblasts from pluripotent bone marrow stem cells (BMSC) [97]. The levels of frizzled-related protein 1, an inhibitor of Wnt/β-catenin signaling, are elevated in mild obesity but decreased in morbid obesity. This leads to an increase in marrow adipose due to the inhibition of the Wnt/β-catenin pathway that drives BMSC differentiation towards osteoblasts [98].

Obesity also affects the composition of the oral and subgingival microbiome. One study revealed that individuals who are overweight or obese have higher levels of Tannerella forsythia in their subgingival biofilms compared to individuals of normal weight [99]. Additionally, individuals with obesity displayed increased levels of T. forsythia, Fusobacterium spp., and Porphyromonas gingivalis in their saliva, irrespective of their periodontal health status [100,101]. Dyslipidemia, characterized by abnormal lipid profiles, also plays a pivotal role in the relationship between metabolic syndrome and periodontitis.

Dyslipidemia and periodontitis

Dyslipidemia is characterized by elevated levels of TG and slightly increased levels of low-density lipoprotein (LDL) with decreased levels of HDL, resulting in an anomalous lipid profile state that predisposes individuals to CVD. Elevated TG levels and decreased HDL levels are elements of MBS, and these factors are interconnected with periodontitis, establishing a bidirectional link [20]. The simultaneous presence of dyslipidemia and periodontitis could potentially be linked to oxidative stress and prolonged systemic inflammation. However, additional research is necessary to elucidate the exact mechanism behind this association [102].

The correlation between periodontitis and dyslipidemia could potentially be influenced by circulating pro-inflammatory cytokines in the bloodstream. It is suggested that periodontitis is not solely associated with decreased lipid metabolism but also contributes to the worsening of hyperlipidemia by increasing the expression of pro-inflammatory cytokines in both serum and gingival crevicular fluid [103].

Changes in lipid and lipoprotein profiles caused by infection or inflammation may result from a variety of mechanisms. These encompass enhanced release of very low-density lipoprotein (VLDL), elevated breakdown of fats in adipose tissue (lipolysis), raised production of fatty acids in the liver, decreased oxidation of fatty acids, and prolonged removal of VLDL due to decreased function of lipoprotein lipase and apolipoprotein-E [104-106]. Nakarai et al. observed that the presence of LPS triggered a rise in the lipolytic function of adipocytes when coexisting with macrophages. Consequently, they hypothesized that periodontal infection could prompt lipolysis and consequently increase the levels of circulating TG [107]. The inhibition of TG clearance or enhancement of their synthesis by LPS and cytokines could potentially play a role in the development of hypertriglyceridemia [108]. Similarly, Arreguin-Cano et al. noted that individuals diagnosed with periodontal disease exhibited elevated blood TG levels, reduced HDL levels, and deteriorated metabolic parameters [109].

During the initial primary stage, the changes in lipids and lipoproteins that occur in response to infectious or inflammatory situations are advantageous to the host due to their involvement in the innate immune system response. For instance, lipoproteins can counteract the effects of bacterial LPS by facilitating its rapid elimination from the bloodstream, diverting it away from monocytes and macrophages, decreasing the activation of immune cells, and reducing the production of cytokines [110]. However, the process of increasing the removal of excess cholesterol from peripheral tissues and its transfer to the liver for elimination is supported by HDL. Apart from this function, HDL also poses properties such as antibacterial, antioxidant, and anti-inflammatory effects. Consequently, a decrease in HDL levels along with an increase in triglycerides and LDL levels leads to a heightened pro-inflammatory state. Additionally, hyperlipidemia induces changes in the body's response to inflammatory stimuli from periodontal pathogens [111].

Serum antibodies against Porphyromonas gingivalis, a widely recognized pathogen associated with periodontitis, are more common in individuals with reduced levels of HDL [112]. Additionally, serum antibodies targeting Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) and P. gingivalis were demonstrated to be increased in individuals with higher levels of LDL cholesterol [113]. In a previous study, mice that were subjected to a high-fat diet and developed metabolic syndrome experienced an increase in the formation of osteoclasts (i.e., osteoclastogenesis), leading to a loss of bone in the alveolar region [114]. The increase in the production of certain pro-inflammatory cytokines such as RANKL, IL-6, macrophage colony-stimulating factor, and monocyte chemoattractant protein-1 was associated with the process of osteoclast formation and the exacerbation of bone loss [114].

The development of systemic inflammation, triggered by the presence of bacteremia and systemic LPS from periodontal disease, is believed to initiate the synthesis of cholesterol. Moreover, a decrease in the levels of pro-inflammatory cytokines in the bloodstream was observed when periodontal treatment was combined with antihyperlipidemic therapy [115]. Lei et al. [116] also noted that a host's susceptibility to periodontitis is increased by hyperlipidemia, which hinders an appropriate immunological response to bacterial damage. Lipids can also disrupt enzyme systems and cell membrane-bound receptors located within cell membranes, leading to the development of periodontal disease. The toll-like receptor (TLR)-2 ligand in isolation did not result in a discernible increase in the tartrate-resistant acid phosphatase-positive cell population. However, a notable escalation in osteoclastogenesis was observed upon the concurrent exposure of TLR-2 with oxidized LDL [117]. Another significant metabolic syndrome component, hypertension, also shares a bidirectional relationship with periodontitis.

Hypertension and periodontitis

Hypertension is a widespread chronic vascular disease that poses a substantial risk to cardiovascular health, characterized by systolic blood pressure surpassing 140 mmHg or diastolic blood pressure exceeding 90 mmHg [1,118]. Periodontitis has been linked to enhanced atherosclerosis [119-121]. The inflammatory response initiated by periodontitis at a systemic level has the potential to contribute to the development of atherosclerosis. This systemic inflammation can result in arterial stiffening and faster pulse wave velocity, both of which serve as indicators of compromised arterial health. The resulting arterial stiffness, caused by the deterioration of the elastic properties of larger arteries, may be involved in the initiation or progression of hypertension [122-125]. Damage can occur to endothelial cells due to periodontal pathogens and their endotoxins, leading to atherogenesis and thrombus formation. The presence of inflammatory mediators from the periodontium can further exacerbate this, elevating the risk of CVD and hypertension [126]. In the pathogenesis of CVD and atherosclerosis, the endothelial inflammatory state induced by toxins discharged from oral bacterial load infiltrating the bloodstream via periodontal pockets serves as a primary stage. Hypertension may emerge as a potential consequence in later stages [127]. A recently conducted research investigation demonstrated that individuals with hypertension exhibited elevated levels of P. intermedia, P. gingivalis, and F. nucleatum compared to patients with normal blood pressure [128]. Interventional research has indicated that periodontal therapy can improve initial indicators of atherosclerosis, including endothelial function, carotid artery intima-media thickness, and pulse-wave velocity [121,129]. According to studies, patients with severe periodontal disease had greater left ventricular mass [122,130-132]. Another study revealed that the application of periodontal therapy led to a notable reduction of 12.5 mmHg in systolic blood pressure and 10 mmHg in diastolic blood pressure. Additionally, six months post-treatment, there was a decrease in CRP and IL-6 levels, and left ventricular mass decreased by 12.9 g [133]. Hypertension is a key factor in the development of metabolic syndrome [72]. A specific study found a connection between the occurrence of hypertension and the intensity of periodontal disease [134]. Another study illustrated a favorable association between hypertension and periodontal disease. Moreover, it suggested an increased vulnerability to the development of periodontal disease in individuals with hypertension when contrasted with those having prehypertension or normotensive status [135].

Conclusions

The bidirectional relationship between MBS and periodontitis involves a complex interplay of systemic and oral health factors, mediated by inflammatory responses, oxidative stress, and shared risk factors. Current evidence emphasizes how these conditions mutually influence each other's pathogenesis, with elevated inflammatory markers like TNF-α, IL-1β, and CRP acting as critical links. Characterized by chronic inflammation and microbial dysbiosis, periodontitis contributes to systemic inflammation through the release of pro-inflammatory cytokines and oxidative stress markers. These exacerbate conditions that are hallmark components of MBS, such as IR, hyperglycemia, central obesity, dyslipidemia, and hypertension. Conversely, MBS exacerbates periodontitis by impairing immune responses, promoting dysbiosis, and increasing local and systemic inflammation. Additionally, the altered microbiome in obesity and diabetes further predisposes individuals to periodontitis.

Clinical studies have underscored the need for integrated therapeutic approaches that address both oral and systemic health to mitigate the bidirectional impacts of these diseases. Such therapeutic strategies should focus on controlling inflammation, improving glycemic control, and modifying lifestyle factors. Furthermore, future research should aim to elucidate the specific molecular pathways and biomarkers that mediate this relationship. Longitudinal studies and randomized controlled trials are essential to establish causality and evaluate treatment effectiveness comprehensively. In conclusion, understanding the interplay between periodontitis and MBS highlights the importance of interdisciplinary collaboration in clinical practice. A holistic approach that addresses both periodontal and systemic health components is crucial for improving patient outcomes and reducing the global burden of chronic inflammatory diseases.

Disclosures

Author Contributions

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Bandar M. Barnawi, Fai A. Al-Mutiri, Ghadeer M. Alghamdi, Ziyad M. Al-Sultan, Ridha I. Almutawah, Waleed K. Mahjoub, Mahdi M. Alsetri, Saud K. Al-Raqqas, Rahaf S. Alqahtani, Maram M. Alanazi, Madhawi S. Al-harbi

Acquisition, analysis, or interpretation of data:  Bandar M. Barnawi, Fai A. Al-Mutiri, Ghadeer M. Alghamdi, Ziyad M. Al-Sultan, Ridha I. Almutawah, Waleed K. Mahjoub, Mahdi M. Alsetri, Saud K. Al-Raqqas, Rahaf S. Alqahtani, Maram M. Alanazi, Madhawi S. Al-harbi

Drafting of the manuscript:  Bandar M. Barnawi, Fai A. Al-Mutiri, Ghadeer M. Alghamdi, Ziyad M. Al-Sultan, Ridha I. Almutawah, Waleed K. Mahjoub, Mahdi M. Alsetri, Saud K. Al-Raqqas, Rahaf S. Alqahtani, Maram M. Alanazi, Madhawi S. Al-harbi

Critical review of the manuscript for important intellectual content:  Bandar M. Barnawi, Fai A. Al-Mutiri, Ghadeer M. Alghamdi, Ziyad M. Al-Sultan, Ridha I. Almutawah, Waleed K. Mahjoub, Mahdi M. Alsetri, Saud K. Al-Raqqas, Rahaf S. Alqahtani, Maram M. Alanazi, Madhawi S. Al-harbi

Supervision:  Bandar M. Barnawi
==== Refs
References

1 The association of periodontitis and metabolic syndrome Dent Res J (Isfahan) Gurav AN 1 10 11 2014 https://pubmed.ncbi.nlm.nih.gov/24688553/ 24688553
2 Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions J Periodontol Papapanou PN Sanz M Buduneli N 0 82 89 Suppl 1 2018
3 Association between chronic periodontal disease and obesity: a systematic review and meta-analysis J Periodontol Chaffee BW Weston SJ 1708 1724 81 2010 20722533
4 Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases J Periodontol Tonetti MS Van Dyke TE 0 9 84 2013
5 Overweight and obesity predict time to periodontal disease progression in men J Clin Periodontol Gorman A Kaye EK Apovian C Fung TT Nunn M Garcia RI 107 114 39 2012 22150475
6 Oxidative stress, systemic inflammation, and severe periodontitis J Dent Res D'Aiuto F Nibali L Parkar M Patel K Suvan J Donos N 1241 1246 89 2010 20739696
7 Association between metabolic syndrome and periodontal disease Aust Dent J Andriankaja OM Sreenivasa S Dunford R DeNardin E 252 259 55 2010 20887511
8 Periodontitis and risk for atherosclerosis: an update on intervention trials J Clin Periodontol Tonetti MS 15 19 36 Suppl 10 2009 19432627
9 Periodontal diseases in North America Periodontol 2000 Albandar JM 31 69 29 2002 12102702
10 Periodontal diseases in Asia and Oceania Periodontol 2000 Corbet EF Zee KY Lo EC 122 152 29 2002 12102706
11 Periodontal diseases in Central and South America Periodontol 2000 Gjermo P Rösing CK Susin C Oppermann R 70 78 29 2002 12102703
12 Periodontal diseases in Europe Periodontol 2000 Sheiham A Netuveli GS 104 121 29 2002 12102705
13 Global, regional, and national prevalence, incidence, and disability-adjusted life years for oral conditions for 195 countries, 1990-2015: a systematic analysis for the Global Burden of Diseases, Injuries, and risk factors J Dent Res Kassebaum NJ Smith AG Bernabé E 380 387 96 2017 28792274
14 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation Grundy SM Cleeman JI Daniels SR 2735 2752 112 2005 16157765
15 The metabolic syndrome Lancet Eckel RH Grundy SM Zimmet PZ 1415 1428 365 2005 15836891
16 Periodontal disease and pregnancy outcomes: state-of-the-science Obstet Gynecol Surv Xiong X Buekens P Vastardis S Yu SM 605 615 62 2007 17705886
17 Banting lecture 1988. Role of insulin resistance in human disease Diabetes Reaven GM 1595 1607 37 1988 3056758
18 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation Alberti KG Eckel RH Grundy SM 1640 1645 120 2009 19805654
19 Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation Kim JA Montagnani M Koh KK Quon MJ 1888 1904 113 2006 16618833
20 Periodontal disease and the metabolic syndrome Int Dent J Lamster IB Pagan M 67 77 67 2017 27861820
21 Metabolic syndrome, or what you will: definitions and epidemiology Diab Vasc Dis Res Day C 32 38 4 2007 17469041
22 Clinical review: association between metabolic syndrome and periodontitis: a systematic review and meta-analysis J Clin Endocrinol Metab Nibali L Tatarakis N Needleman I Tu YK D'Aiuto F Rizzo M Donos N 913 920 98 2013 23386648
23 Global burden of oral conditions in 1990-2010: a systematic analysis J Dent Res Marcenes W Kassebaum NJ Bernabé E Flaxman A Naghavi M Lopez A Murray CJ 592 597 92 2013 23720570
24 Inflammatory mediators in the pathogenesis of periodontitis Expert Rev Mol Med Yucel-Lindberg T Båge T 0 15 2013
25 Systemic markers of inflammation in periodontitis J Periodontol Loos BG 2106 2115 76 Suppl 11S 2005
26 Mapping the pathogenesis of periodontitis: a new look J Periodontol Kornman KS 1560 1568 79 2008 18673011
27 Chronic periodontitis and C-reactive protein levels J Periodontol Gomes-Filho IS Freitas Coelho JM da Cruz SS 969 978 82 2011 21189085
28 Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis J Periodontol Sahingur SE Sharma A Genco RJ De Nardin E 329 337 74 2003 12710752
29 The periodontal anaerobe Porphyromonas gingivalis induced platelet activation and increased aggregation in whole blood by rat model Thromb Res Yu KM Inoue Y Umeda M Terasaki H Chen ZY Iwai T 418 425 127 2011 21334044
30 Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines Pharmacol Res Sorsa T Tervahartiala T Leppilahti J 108 113 63 2011 20937384
31 Serum cytokine levels in periodontitis patients in relation to the bacterial load J Periodontol Andrukhov O Ulm C Reischl H Nguyen PQ Matejka M Rausch-Fan X 885 892 82 2011 21138356
32 Inflammation and bone loss in periodontal disease J Periodontol Cochran DL 1569 1576 79 2008 18673012
33 Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2486 2497 285 2001 11368702
34 Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation Diabet Med Alberti KG Zimmet PZ 539 553 15 1998 9686693
35 Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006 Natl Health Stat Report Ervin RB 1 7 2009 https://pubmed.ncbi.nlm.nih.gov/19634296/
36 Obesity alters composition and diversity of the oral microbiota in patients with type 2 diabetes mellitus independently of glycemic control PLoS One Tam J Hoffmann T Fischer S Bornstein S Gräßler J Noack B 0 13 2018
37 Association between metabolic syndrome and periodontitis: the role of lipids, inflammatory cytokines, altered host response, and the microbiome Periodontol 2000 Pirih FQ Monajemzadeh S Singh N 50 75 87 2021 34463996
38 Relationship of metabolic syndrome to chronic periodontitis J Periodontol Li P He L Sha YQ Luan QX 541 549 80 2009 19335073
39 The association of metabolic syndrome with periodontal disease is confounded by age and smoking in a Korean population: the Shiwha-Banwol Environmental Health Study J Clin Periodontol Han DH Lim SY Sun BC Paek D Kim HD 609 616 37 2010 20492075
40 Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome Indian J Endocrinol Metab Garg MK Dutta MK Mahalle N 116 123 16 2012 22276262
41 Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis J Periodontol Gürkan A Emingil G Saygan BH Cinarcik S Atilla G Köse T Berdeli A 1256 1263 78 2007 17608581
42 Periodontal disease as part of the insulin resistance syndrome in diabetic patients J Int Acad Periodontol Nishimura F Soga Y Iwamoto Y Kudo C Murayama Y 16 20 7 2005 https://pubmed.ncbi.nlm.nih.gov/15736891/ 15736891
43 Moderate and severe periodontitis are positively associated with metabolic syndrome Clin Oral Investig Gomes-Filho IS Balinha ID da Cruz SS 3719 3727 25 2021
44 Periodontitis severity relationship with metabolic syndrome: a systematic review with meta-analysis Oral Dis Rosário-Dos-Santos HL Miranda SS Gomes-Filho IS 2512 2520 29 2023 36346175
45 The association between periodontal disease severity and metabolic syndrome in Vietnamese patients Int J Dent Hyg Pham T 484 491 16 2018 29900658
46 Periodontitis and insulin resistance: casual or causal relationship? Diabetes Metab J Gurav AN 404 411 36 2012 23275933
47 Insulin Resistance & Prediabetes 5 2024 2018 https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
48 Relation of periodontitis and metabolic syndrome with gestational glucose metabolism disorder J Periodontol Bullon P Jaramillo R Santos-Garcia R Rios-Santos V Ramirez M Fernandez-Palacin A Fernandez-Riejos P 0 8 85 2014
49 Metabolic syndrome and periodontitis: is oxidative stress a common link? J Dent Res Bullon P Morillo JM Ramirez-Tortosa MC Quiles JL Newman HN Battino M 503 518 88 2009 19587154
50 Insulin and insulin resistance Clin Biochem Rev Wilcox G 19 39 26 2005 https://pubmed.ncbi.nlm.nih.gov/16278749/ 16278749
51 Inflammation: the link between insulin resistance, obesity and diabetes Trends Immunol Dandona P Aljada A Bandyopadhyay A 4 7 25 2004 14698276
52 Metabolic syndrome, insulin resistance, and periodontitis: a cross-sectional study in a middle-aged French population J Clin Periodontol Benguigui C Bongard V Ruidavets JB Chamontin B Sixou M Ferrières J Amar J 601 608 37 2010 20492076
53 Periodontal infection, systemic inflammation, and insulin resistance: results from the continuous National Health and Nutrition Examination Survey (NHANES) 1999-2004 Diabetes Care Demmer RT Squillaro A Papapanou PN Rosenbaum M Friedewald WT Jacobs DR Jr Desvarieux M 2235 2242 35 2012 22837370
54 Periodontal disease, systemic inflammation and adipocytokines: effect of periodontal therapy on glycaemic control in type 2 diabetes mellitus (T2DM) patients Diabetes Obes Metab Abou-Raya A Abou-Raya S AbuElKheir H 76 12 2010 21029303
55 Changes in inflammatory and metabolic parameters after periodontal treatment in patients with and without obesity J Periodontol Altay U Gürgan CA Ağbaht K 13 23 84 2013 22348694
56 Periodontal disease: the influence of metabolic syndrome Nutr Metab (Lond) Marchetti E Monaco A Procaccini L 88 9 2012 23009606
57 Porphyromonas gingivalis lipopolysaccharide upregulates insulin secretion from pancreatic β cell line MIN6 J Periodontol Bhat UG Ilievski V Unterman TG Watanabe K 1629 1636 85 2014 24921432
58 Type 2 diabetes can be prevented with early pharmacological intervention Diabetes Care DeFronzo RA Abdul-Ghani M 34 2011
59 Inflammation and insulin resistance J Clin Invest Shoelson SE Lee J Goldfine AB 1793 1801 116 2006 16823477
60 Recent advances in the relationship between obesity, inflammation, and insulin resistance Eur Cytokine Netw Bastard JP Maachi M Lagathu C 4 12 17 2006 https://pubmed.ncbi.nlm.nih.gov/16613757/ 16613757
61 Diabetes and periodontitis J Indian Soc Periodontol Deshpande K Jain A Sharma R Prashar S Jain R 207 212 14 2010 21731243
62 Comparison of neutrophil functions in diabetic and healthy subjects with chronic generalized periodontitis J Indian Soc Periodontol Shetty N Thomas B Ramesh A 41 44 12 2008 20142943
63 Respiratory burst of neutrophils in diabetic patients with periodontal disease Ann N Y Acad Sci De Toni S Piva E Lapolla A Fontana G Fedele D Plebani M 363 367 832 1997 9704064
64 Oxidative and inflammatory status in Type 2 diabetes patients with periodontitis J Clin Periodontol Allen EM Matthews JB O' Halloran DJ Griffiths HR Chapple IL 894 901 38 2011 21883360
65 Oxidative stress and diabetic complications Circ Res Giacco F Brownlee M 1058 1070 107 2010 21030723
66 Diabetes mellitus related bone metabolism and periodontal disease Int J Oral Sci Wu YY Xiao E Graves DT 63 72 7 2015 25857702
67 Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress J Diabetes Res Yan LJ 137919 2014 2014 25019091
68 MMP-2 salivary activity in type 2 diabetes mellitus patients Diabetol Metab Syndr Arreguin-Cano JA Ayerdi-Nájera B Tacuba-Saavedra A 113 11 2019 31892956
69 Periodontal disease and diabetes mellitus J Appl Oral Sci Negrato CA Tarzia O Jovanovič L Chinellato LE 1 12 21 2013 23559105
70 Changes of saliva microbiota in the onset and after the treatment of diabetes in patients with periodontitis Aging (Albany NY) Yang Y Liu S Wang Y 13090 13114 12 2020 32634783
71 Relative reduction of biological and phylogenetic diversity of the oral microbiota of diabetes and pre-diabetes patients Microb Pathog Saeb AT Al-Rubeaan KA Aldosary K Udaya Raja GK Mani B Abouelhoda M Tayeb HT 215 229 128 2019 30625362
72 Periodontal disease and its association with metabolic syndrome-a comprehensive review Int J Mol Sci Aizenbud I Wilensky A Almoznino G 24 2023
73 The subgingival microbiome associated with periodontitis in type 2 diabetes mellitus ISME J Shi B Lux R Klokkevold P Chang M Barnard E Haake S Li H 519 530 14 2020 31673077
74 A tale of two risks: smoking, diabetes and the subgingival microbiome ISME J Ganesan SM Joshi V Fellows M 2075 2089 11 2017 28534880
75 Periodontal treatment and HbA1c levels in subjects with diabetes mellitus J Oral Rehabil Altamash M Klinge B Engström PE 31 38 43 2016 26332936
76 Periodontal disease: a risk factor for diabetes and cardiovascular disease Int J Mol Sci Liccardo D Cannavo A Spagnuolo G Ferrara N Cittadini A Rengo C Rengo G 20 2019
77 Periodontal diseases and diabetes mellitus: a systematic review J Pharm Bioallied Sci Alwithanani N 0 63 15 2023
78 Metabolic syndrome - a new definition and management guidelines: a joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons Arch Med Sci Dobrowolski P Prejbisz A Kuryłowicz A 1133 1156 18 2022 36160355
79 Global Status Report on Noncommunicable Diseases World Health Organisation Geneva World Health Organisation 2014 https://www.who.int/publications/i/item/9789241564854
80 Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 0 253 i-xii, 1-253 894 2000 https://pubmed.ncbi.nlm.nih.gov/11234459/
81 Adiposity and fat distribution outcome measures: assessment and clinical implications Obes Res Aronne LJ Segal KR 14 21 10 Suppl 1 2002 11786597
82 Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity Nat Rev Endocrinol Ross R Neeland IJ Yamashita S 177 189 16 2020 32020062
83 WHO European Regional Obesity Report 8 2024 2022 https://iris.who.int/handle/10665/353747
84 Obesity and Its Complications: Practical Diagnostic and Therapeutic Recommendations [Polish] Wydawnictwo Lekarskie PZWL, Warszawa Ostrowska OL Bogdański P Mamcarz A Warsaw PZWL Medical Publishing House 2021
85 Association between severity of body mass index and periodontal condition in women Clin Oral Investig Pataro AL Costa FO Cortelli SC 727 734 16 2012
86 Association between periodontal disease and overweight and obesity: a systematic review J Periodontol Keller A Rohde JF Raymond K Heitmann BL 766 776 86 2015 25672656
87 Relationship between increases in BMI and changes in periodontal status: a prospective cohort study J Clin Periodontol Ekuni D Mizutani S Kojima A 772 778 41 2014 24813869
88 Obesity and infection Lancet Infect Dis Falagas ME Kompoti M 438 446 6 2006 16790384
89 Inflammatory mechanisms linking obesity and metabolic disease J Clin Invest Saltiel AR Olefsky JM 1 4 127 2017 28045402
90 Inflammation and metabolic disorders Nature Hotamisligil GS 860 867 444 2006 17167474
91 Obesity, inflammation, and periodontal disease J Dent Res Pischon N Heng N Bernimoulin JP Kleber BM Willich SN Pischon T 400 409 86 2007 17452558
92 Adipose tissue macrophages: their role in adipose tissue remodeling J Leukoc Biol Suganami T Ogawa Y 33 39 88 2010 20360405
93 Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome Mol Cell Endocrinol Maury E Brichard SM 1 16 314 2010 19682539
94 Adipose tissue as an active endocrine organ: recent advances Curr Opin Pharmacol Gimeno RE Klaman LD 122 128 5 2005 15780819
95 Visceral fat area-defined obesity and periodontitis among Koreans J Clin Periodontol Han DH Lim SY Sun BC Paek DM Kim HD 172 179 37 2010 20041978
96 Tumor necrosis factor- α and interleukin-6: potential interorgan inflammatory mediators contributing to destructive periodontal disease in obesity or metabolic syndrome Mediators Inflamm Khosravi R Ka K Huang T Khalili S Nguyen BH Nicolau B Tran SD 728987 2013 2013 24068858
97 Defining osteoblast and adipocyte lineages in the bone marrow Bone Pierce JL Begun DL Westendorf JJ McGee-Lawrence ME 2 7 118 2019 29782940
98 Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity Int J Obes (Lond) Lagathu C Christodoulides C Tan CY 1695 1705 34 2010 20514047
99 The relation between periodontopathogenic bacterial levels and resistin in the saliva of obese type 2 diabetic patients J Diabetes Res Al-Rawi N Al-Marzooq F 2643079 2017 2017 29138754
100 Does obesity influence the subgingival microbiota composition in periodontal health and disease? J Clin Periodontol Maciel SS Feres M Gonçalves TE Zimmermann GS da Silva HD Figueiredo LC Duarte PM 1003 1012 43 2016 27717180
101 Subgingival microbiota in overweight and obese young adults with no destructive periodontal disease J Periodontol de Andrade DR Silva PA Colombo AP Silva-Boghossian CM 1410 1419 92 2021 33386623
102 Role of systemic markers in periodontal diseases: a possible inflammatory burden and risk factor for cardiovascular diseases? Ann Med Health Sci Res Kalburgi V Sravya L Warad S Vijayalaxmi K Sejal P Hazeil Dj 388 392 4 2014 24971214
103 Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia J Clin Periodontol Fentoğlu Ö Köroğlu BK Hiçyılmaz H 8 16 38 2011 21062339
104 Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host J Lipid Res Khovidhunkit W Kim MS Memon RA Shigenaga JK Moser AH Feingold KR Grunfeld C 1169 1196 45 2004 15102878
105 Pathophysiological relationships between periodontitis and systemic disease: recent concepts involving serum lipids J Periodontol Iacopino AM Cutler CW 1375 1384 71 2000 10972656
106 Beneficial effects of cytokine induced hyperlipidemia Z Ernahrungswiss Feingold KR Hardardóttir I Grunfeld C 66 74 37 Suppl 1 1998 https://pubmed.ncbi.nlm.nih.gov/9558731/ 9558731
107 Periodontal disease and hypertriglyceridemia in Japanese subjects: potential association with enhanced lipolysis Metabolism Nakarai H Yamashita A Takagi M 823 829 60 2011 20817211
108 Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance J Lipid Res Feingold K Staprans I Memon R 1765 1776 33 1992 1479286
109 Relationship between metabolic syndrome and diagnoses of periodontal diseases among participants in a large Taiwanese cohort J Clin Periodontol Tu YK D'Aiuto F Lin HJ Chen YW Chien KL 994 1000 40 2013 24007401
110 Dyslipidemia and inflammation: an evolutionary conserved mechanism Clin Nutr Esteve E Ricart W Fernández-Real JM 16 31 24 2005 15681098
111 Hyperlipidemia causes changes in inflammatory responses to periodontal pathogen challenge: implications in acute and chronic infections Arch Oral Biol Chen S Lin G You X 1075 1084 59 2014 24992577
112 Serum antibody to Porphyromonas gingivalis in metabolic syndrome among an older Japanese population Gerodontology Iwasaki M Minagawa K Sato M Kaneko N Imai S Yoshihara A Miyazaki H 193 200 33 2016 24924482
113 Association between periodontal disease and plasma levels of cholesterol and triglycerides Colomb Med (Cali) Jaramillo A Lafaurie GI Millán LV 80 86 44 2013 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002029/ 24892452
114 Metabolic syndrome exacerbates inflammation and bone loss in periodontitis J Dent Res Li Y Lu Z Zhang X Yu H Kirkwood KL Lopes-Virella MF Huang Y 362 370 94 2015 25503900
115 Proinflammatory cytokine levels in hyperlipidemic patients with periodontitis after periodontal treatment Oral Dis Fentoğlu O Kirzioğlu FY Ozdem M Koçak H Sütçü R Sert T 299 306 18 2012 22151458
116 Hyperlipidemia impaired innate immune response to periodontal pathogen porphyromonas gingivalis in apolipoprotein E knockout mice PLoS One Lei L Li H Yan F Xiao Y 0 8 2013
117 Toll-like receptor 2 activation primes and upregulates osteoclastogenesis via lox-1 Lipids Health Dis Ohgi K Kajiya H Goto-T K Okamoto F Yoshinaga Y Okabe K Sakagami R 132 17 2018 29859535
118 2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J Williams B Mancia G Spiering W 3021 3104 39 2018 30165516
119 Is there an association between periodontitis and atherosclerosis in adults? A systematic review Curr Vasc Pharmacol Almeida AP Fagundes NC Maia LC Lima RR 569 582 16 2018 28875830
120 Periodontitis and arterial stiffness: a systematic review and meta-analysis J Clin Periodontol Schmitt A Carra MC Boutouyrie P Bouchard P 977 987 42 2015 26465940
121 Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis Atherosclerosis Orlandi M Suvan J Petrie A 39 46 236 2014 25014033
122 Blood pressure and left ventricular mass in subjects with type 2 diabetes and gingivitis or chronic periodontitis J Clin Periodontol Franek E Napora M Blach A 875 880 37 2010 20796107
123 Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation Arterioscler Thromb Vasc Biol Amar S Gokce N Morgan S Loukideli M Van Dyke TE Vita JA 1245 1249 23 2003 12763762
124 Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals Circulation Vlachopoulos C Dima I Aznaouridis K 2193 2200 112 2005 16186422
125 Periodontitis and blood pressure: the concept of dental hypertension Atherosclerosis Tsioufis C Kasiakogias A Thomopoulos C Stefanadis C 1 9 219 2011 21640351
126 Porphyromonas gingivalis infection and cell death in human aortic endothelial cells FEMS Microbiol Lett Roth GA Ankersmit HJ Brown VB Papapanou PN Schmidt AM Lalla E 106 113 272 2007 17459112
127 Is there an association between periodontitis and hypertension? Curr Cardiol Rev Macedo Paizan ML Vilela-Martin JF 355 361 10 2014 24739001
128 Higher frequency of specific periodontopathogens in hypertensive patients. A pilot study Braz Dent J Silveira TM Silva CF Vaucher RA Angst PD Casarin M Pola NM 64 73 33 2022 36287500
129 Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness FASEB J Piconi S Trabattoni D Luraghi C 1196 1204 23 2009 19074511
130 Evaluating periodontal risk for patients at risk of or suffering from atherosclerosis: recent biological hypotheses and therapeutic consequences Arch Cardiovasc Dis Huck O Saadi-Thiers K Tenenbaum H 352 358 104 2011 21693372
131 Association between periodontal disease and left ventricle mass in essential hypertension Hypertension Angeli F Verdecchia P Pellegrino C 488 492 41 2003 12623948
132 Association between chronic periodontal disease and left ventricular hypertrophy in kidney transplant recipients Transplantation Franek E Blach A Witula A Kolonko A Chudek J Drugacz J Wiecek A 3 5 80 2005 16003224
133 Non-surgical periodontal treatment reduces cardiovascular risk in refractory hypertensive patients: a pilot study J Clin Periodontol Vidal F Cordovil I Figueredo CM Fischer RG 681 687 40 2013 23639076
134 Association between hypertension and chronic periodontitis in a Portuguese population Ann Med Xavier I Botelho J Machado V Rua J Sintra Delgado A João Mendes J 132 51 2019
135 Relationship between prehypertension/hypertension and periodontal disease: a prospective cohort study Am J Hypertens Kawabata Y Ekuni D Miyai H 388 396 29 2016 26208668
